Amido-substituted azole compounds

US9884063B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Knut Eis · Berlin, DE
• Jens Ackerstaff · Mülheim an der Ruhr, DE
• Sarah WAGNER · Berlin, DE
• Daniel BASTING
• Stefan Golz · Wetter (Ruhr), DE
• Eckhard Bender · Langenfeld, DE
• Volkhart Min-Jian Li · Velbert, DE
• Philip Lienau · Berlin, DE
• Ningshu Liu · Berlin, DE
• Franziska SIEGEL · Cambridge, US
• Marcus Bauser · Berlin, DE
• Detlev Sülzle · Berlin, DE
• Simon Holton · Berlin, DE
• Michaela BAIRLEIN · Wuppertal, DE
• Philipp Buchgraber · Leverkusen, DE
• Jozsef Balint · Berlin, DE

Key dates

• Filing date: Apr 1, 2015
• Grant date: Feb 6, 2018
• Expiry date: Apr 1, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.